Related references
Note: Only part of the references are listed.Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance
Stephen J. Nicholls et al.
AMERICAN HEART JOURNAL (2021)
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study
Kausik K. Ray et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2021)
Mechanisms of statin-associated skeletal muscle-associated symptoms
Jamal Bouitbir et al.
PHARMACOLOGICAL RESEARCH (2020)
Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy
Christie M. Ballantyne et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2020)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia
Maciej Banach et al.
JAMA CARDIOLOGY (2020)
Bempedoic acid for high-risk patients with CVD as adjunct lipid-lowering therapy: A cost-effectiveness analysis
Kanila Perera et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2020)
Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials
Harold E. Bays et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2020)
Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: Analysis of pooled patient-level data from phase 3 clinical trials
P.B. Duell et al.
ATHEROSCLEROSIS (2020)
Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis
Amy C. Burke et al.
CURRENT OPINION IN LIPIDOLOGY (2019)
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial
Narendra D. Lalwani et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
Association between statin treatment and new-onset diabetes mellitus: a population based case-control study
Dong-Won Kim et al.
DIABETOLOGY & METABOLIC SYNDROME (2019)
Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance
Ulrich Laufs et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial
Anne C. Goldberg et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Tendon pathology in hypercholesterolaemia patients: Epidemiology, pathogenesis and management
Yang Yang et al.
JOURNAL OF ORTHOPAEDIC TRANSLATION (2019)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
Scott M. Grundy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
Christie M. Ballantyne et al.
ATHEROSCLEROSIS (2018)
Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
Dennis T. Ko et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial
Dhruv S. Kazi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Statin use and risk of new-onset diabetes: A meta-analysis of observational studies
M. Casula et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2017)
Targeting ATP-Citrate Lyase in Hyperlipidemia and Metabolic Disorders
Stephen L. Pinkosky et al.
TRENDS IN MOLECULAR MEDICINE (2017)
Renal Drug Transporters and Drug Interactions
Anton Ivanyuk et al.
CLINICAL PHARMACOKINETICS (2017)
AMPK signalling in health and disease
David Carling
CURRENT OPINION IN CELL BIOLOGY (2017)
Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement
Maciej Banach et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012
Nathan D. Wong et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2016)
Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
Stephen L. Pinkosky et al.
NATURE COMMUNICATIONS (2016)
Is Statin Use Associated With Tendon Rupture? A Population-Based Retrospective Cohort Analysis
Tahmeed Contractor et al.
AMERICAN JOURNAL OF THERAPEUTICS (2015)
Cardiovascular drugs that increase the risk of new-onset diabetes
Kwok Leung Ong et al.
AMERICAN HEART JOURNAL (2014)
The Incidence of Kidney Injury for Patients Treated With a High-Potency Versus Moderate-Potency Statin Regimen After an Acute Coronary Syndrome
Amy Sarma et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2014)
AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism
Stephen L. Pinkosky et al.
JOURNAL OF LIPID RESEARCH (2013)
OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies
Megan Roth et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
A Survey of the FDA's AERS Database Regarding Muscle and Tendon Adverse Events Linked to the Statin Drug Class
Keith B. Hoffman et al.
PLOS ONE (2012)
Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy A Meta-analysis
David Preiss et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Renal Secretion of Uric Acid by Organic Anion Transporter 2 (OAT2/SLC22A7) in Human
Masanobu Sato et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Tendinous disorders attributed to statins:: A study on ninety-six spontaneous reports in the period 1990-2005 and review of the literature
Isabelle Marie et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Tendon rupture associated with simastatin/ezetimibe therapy
Raja C. Pullatt et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
AMP-activated protein kinase in the heart - Role during health and disease
Michael Arad et al.
CIRCULATION RESEARCH (2007)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia
HE Bays et al.
CLINICAL THERAPEUTICS (2004)
Share Paper
